Literature DB >> 28559429

RNA Binding Protein CUGBP1 Inhibits Liver Cancer in a Phosphorylation-Dependent Manner.

Kyle Lewis1,2,3, Leila Valanejad1, Ashley Cast1, Mary Wright1, Christina Wei4, Polina Iakova3, Lauren Stock4, Rebekah Karns5, Lubov Timchenko4, Nikolai Timchenko6,3.   

Abstract

Despite intensive investigations, mechanisms of liver cancer are not known. Here, we identified an important step of liver cancer, which is the neutralization of tumor suppressor activities of an RNA binding protein, CUGBP1. The translational activity of CUGBP1 is activated by dephosphorylation at Ser302. We generated CUGBP1-S302A knock-in mice and found that the reduction of translational activity of CUGBP1 causes development of a fatty liver phenotype in young S302A mice. Examination of liver cancer in diethylnitrosamine (DEN)-treated CUGBP1-S302A mice showed these mice develop much more severe liver cancer that is associated with elimination of the mutant CUGBP1. Searching for mechanisms of this elimination, we found that the oncoprotein gankyrin (Gank) preferentially binds to and triggers degradation of dephosphorylated CUGBP1 (de-ph-S302-CUGBP1) or S302A mutant CUGBP1. To test the role of Gank in degradation of CUGBP1, we generated mice with liver-specific deletion of Gank. In these mice, the tumor suppressor isoform of CUGBP1 is protected from Gank-mediated degradation. Consistent with reduction of CUGBP1 in animal models, CUGBP1 is reduced in patients with pediatric liver cancer. Thus, this work presents evidence that de-ph-S302-CUGBP1 is a tumor suppressor protein and that the Gank-UPS-mediated reduction of CUGBP1 is a key event in the development of liver cancer.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  C/EBP; C/EBPβ; CUGBP1; HBL; HCC; gankyrin; phosphorylation

Mesh:

Substances:

Year:  2017        PMID: 28559429      PMCID: PMC5533886          DOI: 10.1128/MCB.00128-17

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  34 in total

Review 1.  Spectrum of molecular changes during hepatocarcinogenesis induced by DEN and other chemicals in Fischer 344 male rats.

Authors:  In Kyoung Lim
Journal:  Mech Ageing Dev       Date:  2002-11       Impact factor: 5.432

2.  Age-specific CUGBP1-eIF2 complex increases translation of CCAAT/enhancer-binding protein beta in old liver.

Authors:  Lubov T Timchenko; Elizabeth Salisbury; Guo-Li Wang; Heather Nguyen; Jeffrey H Albrecht; John W B Hershey; Nikolai A Timchenko
Journal:  J Biol Chem       Date:  2006-08-24       Impact factor: 5.157

3.  Reduced stability of retinoblastoma protein by gankyrin, an oncogenic ankyrin-repeat protein overexpressed in hepatomas.

Authors:  H Higashitsuji; K Itoh; T Nagao; S Dawson; K Nonoguchi; T Kido; R J Mayer; S Arii; J Fujita
Journal:  Nat Med       Date:  2000-01       Impact factor: 53.440

4.  Enhancer-Mediated Oncogenic Function of the Menin Tumor Suppressor in Breast Cancer.

Authors:  Koen M A Dreijerink; Anna C Groner; Erica S M Vos; Alba Font-Tello; Lei Gu; David Chi; Jaime Reyes; Jennifer Cook; Elgene Lim; Charles Y Lin; Wouter de Laat; Prakash K Rao; Henry W Long; Myles Brown
Journal:  Cell Rep       Date:  2017-03-07       Impact factor: 9.423

5.  Elimination of C/EBPalpha through the ubiquitin-proteasome system promotes the development of liver cancer in mice.

Authors:  Guo-Li Wang; Xiurong Shi; Simon Haefliger; Jingling Jin; Angela Major; Polina Iakova; Milton Finegold; Nikolai A Timchenko
Journal:  J Clin Invest       Date:  2010-07       Impact factor: 14.808

6.  Conserved GU-rich elements mediate mRNA decay by binding to CUG-binding protein 1.

Authors:  Irina A Vlasova; Nuzha M Tahoe; Danhua Fan; Ola Larsson; Bernd Rattenbacher; Julius R Sternjohn; Jayprakash Vasdewani; George Karypis; Cavan S Reilly; Peter B Bitterman; Paul R Bohjanen
Journal:  Mol Cell       Date:  2008-02-01       Impact factor: 17.970

7.  Age-associated change of C/EBP family proteins causes severe liver injury and acceleration of liver proliferation after CCl4 treatments.

Authors:  Il-Hwa Hong; Kyle Lewis; Polina Iakova; Jingling Jin; Emily Sullivan; Nicole Jawanmardi; Lubov Timchenko; Nikolai Timchenko
Journal:  J Biol Chem       Date:  2013-11-22       Impact factor: 5.157

8.  The Janus-faced Nature of miR-22 in Hematopoiesis: Is It an Oncogenic Tumor Suppressor or Rather a Tumor-Suppressive Oncogene?

Authors:  Alexander Arthur Wurm; Daniel G Tenen; Gerhard Behre
Journal:  PLoS Genet       Date:  2017-01-12       Impact factor: 5.917

9.  Gankyrin has an antioxidative role through the feedback regulation of Nrf2 in hepatocellular carcinoma.

Authors:  Chun Yang; Ye-Xiong Tan; Guang-Zhen Yang; Jian Zhang; Yu-Fei Pan; Chen Liu; Jing Fu; Yao Chen; Zhi-Wen Ding; Li-Wei Dong; Hong-Yang Wang
Journal:  J Exp Med       Date:  2016-04-18       Impact factor: 14.307

10.  miR-22 has a potent anti-tumour role with therapeutic potential in acute myeloid leukaemia.

Authors:  Xi Jiang; Chao Hu; Stephen Arnovitz; Jason Bugno; Miao Yu; Zhixiang Zuo; Ping Chen; Hao Huang; Bryan Ulrich; Sandeep Gurbuxani; Hengyou Weng; Jennifer Strong; Yungui Wang; Yuanyuan Li; Justin Salat; Shenglai Li; Abdel G Elkahloun; Yang Yang; Mary Beth Neilly; Richard A Larson; Michelle M Le Beau; Tobias Herold; Stefan K Bohlander; Paul P Liu; Jiwang Zhang; Zejuan Li; Chuan He; Jie Jin; Seungpyo Hong; Jianjun Chen
Journal:  Nat Commun       Date:  2016-04-26       Impact factor: 14.919

View more
  11 in total

1.  Molecular signatures of aggressive pediatric liver cancer.

Authors:  Michael E Johnston; Nikolai Timchenko
Journal:  Arch Stem Cell Ther       Date:  2021

2.  Correction of Glycogen Synthase Kinase 3β in Myotonic Dystrophy 1 Reduces the Mutant RNA and Improves Postnatal Survival of DMSXL Mice.

Authors:  Mei Wang; Wen-Chin Weng; Lauren Stock; Diana Lindquist; Ana Martinez; Genevieve Gourdon; Nikolai Timchenko; Mike Snape; Lubov Timchenko
Journal:  Mol Cell Biol       Date:  2019-10-11       Impact factor: 4.272

Review 3.  RNA Binding Proteins in Intestinal Epithelial Biology and Colorectal Cancer.

Authors:  Priya Chatterji; Anil K Rustgi
Journal:  Trends Mol Med       Date:  2018-04-05       Impact factor: 15.272

4.  PARP1 activation increases expression of modified tumor suppressors and pathways underlying development of aggressive hepatoblastoma.

Authors:  Leila Valanejad; Ashley Cast; Mary Wright; Karl-Dimiter Bissig; Rebekah Karns; Matthew T Weirauch; Nikolai Timchenko
Journal:  Commun Biol       Date:  2018-06-11

5.  Small Molecule Cjoc42 Improves Chemo-Sensitivity and Increases Levels of Tumor Suppressor Proteins in Hepatoblastoma Cells and in Mice by Inhibiting Oncogene Gankyrin.

Authors:  Amber M D'Souza; Ashley Cast; Meenasri Kumbaji; Maria Rivas; Ruhi Gulati; Michael Johnston; David Smithrud; James Geller; Nikolai Timchenko
Journal:  Front Pharmacol       Date:  2021-03-04       Impact factor: 5.988

6.  Probing the role of PPARγ in the regulation of late-onset Alzheimer's disease-associated genes.

Authors:  Julio Barrera; Shobana Subramanian; Ornit Chiba-Falek
Journal:  PLoS One       Date:  2018-05-03       Impact factor: 3.240

7.  Gankyrin Promotes Tumor-Suppressor Protein Degradation to Drive Hepatocyte Proliferation.

Authors:  Amber M D'Souza; Yanjun Jiang; Ashley Cast; Leila Valanejad; Mary Wright; Kyle Lewis; Meenasri Kumbaji; Sheeniza Shah; David Smithrud; Rebekah Karns; Soona Shin; Nikolai Timchenko
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2018-05-24

8.  Liver Proliferation Is an Essential Driver of Fibrosis in Mouse Models of Nonalcoholic Fatty Liver Disease.

Authors:  Ashley Cast; Meenasri Kumbaji; Amber D'Souza; Katherine Rodriguez; Anita Gupta; Rebekah Karns; Lubov Timchenko; Nikolai Timchenko
Journal:  Hepatol Commun       Date:  2019-07-17

9.  RNA binding protein CUGBP1 mediates the liver metastasis of colorectal cancer by regulating the ErbB signal pathway.

Authors:  Zhi-Peng Qi; Zhang-Han Chen; Dong-Li He; Shi-Lun Cai; Bing Li; Di Sun; Zhen-Tao Lv; En-Pan Xu; Qiang Shi; Yun-Shi Zhong; Jian-Min Xu
Journal:  Transl Cancer Res       Date:  2021-07       Impact factor: 1.241

10.  Olaparib Inhibits Tumor Growth of Hepatoblastoma in Patient-Derived Xenograft Models.

Authors:  Michael Edward Johnston; Maria Prates Rivas; Delphine Nicolle; Aurore Gorse; Ruhi Gulati; Meenasri Kumbaji; Matthew T Weirauch; Alexander Bondoc; Stefano Cairo; James Geller; Gregory Tiao; Nikolai Timchenko
Journal:  Hepatology       Date:  2021-08-10       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.